<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942174</url>
  </required_header>
  <id_info>
    <org_study_id>9144</org_study_id>
    <nct_id>NCT01942174</nct_id>
  </id_info>
  <brief_title>VACcination In Methotrexate Treated Rheumatoid Arthritis Patients</brief_title>
  <acronym>VACIMRA</acronym>
  <official_title>Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cochin Hospital, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the rate of immunological answer 1 month after antipneumococcal vaccination by
      the conjugated vaccine Prevenar13 ® in patients suffered from rheumatoid polyarthritis and
      who begin a treatement by methotrexate either in the same time, either 1 month later.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffering from rheumatoid polyarthritis have an increased risk to develop an
      infection compared to general population, with a more important mortality risk because
      pneumococcus is considered as one of the major pathogenic agents. Antipneumcoccal vaccination
      is recommended to patients suffering from chronic inflammatory rheumatism treated with
      immunosuppressants. Methotrexate is a long term treatment used in first intention for
      rheumatoid polyarthritis. A recent study shows a decrease of efficacity of antipneumoccal
      vaccination for patients suffering from rheumatoid polyarthritis treated by methotrexate. The
      tested hypothesis will be the presence of better vaccinal protection for patients suffered
      from rheumatoid polyarthritis after 1 month between antipneumococcal vaccination and the
      initiation of methotrexate. The objective is to compare immunologic response for
      antipneumococcal vaccination between patients who are vaccinated in the same time of
      initiation of methotrexate and patients who are vaccinated 1 month before the beginning of
      the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2013</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of immunological positive answer 1 month after antipneumococcal vaccination by the conjugated vaccine Prevenar13 ® in patients suffering from rheumatoid polyarthritis.</measure>
    <time_frame>1 month</time_frame>
    <description>Patient who begins a treatement by methotrexate either in the same time, either 1 month later.
An answer will be considered as positive if the patient answers in at least 3 on 5 of interest serotypes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients in each group who will know fully immunological answer to 5 interest serotypes after the first antipneumococcal vaccination (Prevenar13)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in each group who will know an immunological answer to 13 serotypes after the first antipneumococcal vaccination (Prevenar13)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who will know a fully immunological answer (13 serotypes of vaccine) after a antipneumococcal revaccination with Pneumo 23.</measure>
    <time_frame>3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who will suffer from adverse events in relation with the antipneumococcal vaccination</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of occurence of disease spurts from the first vaccination until the end of the study</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurence of the pneumococcal disease from the first vaccination to the end of the study.</measure>
    <time_frame>1, 6, 7 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Immediate group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.
Interventions : biological/vaccine and drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>period group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.
A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination
Interventions : biological/vaccine and drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>Vaccination at the beginning of the study (day 0)</description>
    <arm_group_label>Immediate group</arm_group_label>
    <arm_group_label>period group</arm_group_label>
    <other_name>Antipneumococcal vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumo23 / Pneumovax</intervention_name>
    <description>Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company</description>
    <arm_group_label>Immediate group</arm_group_label>
    <arm_group_label>period group</arm_group_label>
    <other_name>Antipneumococcal vaccination</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate - Immediate</intervention_name>
    <description>concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13</description>
    <arm_group_label>Immediate group</arm_group_label>
    <other_name>conventional methotrexate treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate - Delay</intervention_name>
    <description>For &quot;period group&quot;, methotrexate is Initiated &amp; month after the antipneumococcal vaccination by prevenar 13</description>
    <arm_group_label>period group</arm_group_label>
    <other_name>Experimental methotrexate treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (&gt;18 yeas old) suffers from rheumatoid arthritis considering ACR/EULAR 2010
             criteria

          -  Rheumatoid arthritis considering 3,2&lt;DAS&lt;5,1

          -  Patient did not treat by long term treatment or has stopped a treatment by
             sulfasalazine, hydroxychloroquine or methotrexate for at least 3 months

          -  Patient has never treated by biotherapy

          -  Patient has never vaccinated against pneumococcal

          -  Patient has signed study consent form

        Exclusion Criteria:

          -  Patient has ever treated by leflunomide or has treated previously by leflunomide (last
             3 months)

          -  Patient is currently treated by methotrexate or has treated previously by methotrexate
             (last 3 months)

          -  Contraindication to methotrexate: renal insuffisance, alcoolic, chronic hepatisis,
             infectious condition, AIDS, hematological failure (cytopeny), pregnancy, obesity,
             diabet, respiratory disease, gastric ulcer

          -  Contraindication to corticotherapy

          -  Pregnancy or pregancy wish

          -  Nursing

          -  Absence of oral contraception for women of childbearing age

          -  Patient of age protected by law et deprived of liberty

          -  Subject who refuses to be vaccinated against pneumococcis agent

          -  Previous history of vaccination allergy (anaphylactic shok, Quincke oedema...)

          -  Gluten hypersensivity or intolerance

          -  Other vaccination during the last month before inclusion

          -  Ig perfusion during the last 3 months period before the study inclusion or during the
             study duration

          -  Patient currently treated by anticoagulant or has not been stopped for at least 48h
             before the study inclusion or hemostasis failure which is contraindicated with
             muscular injection

          -  Participation with an other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques MOREL, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques MOREL, PU-PH</last_name>
    <phone>334 67 33 91 71</phone>
    <email>j-morel@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire CHAUVETON, PharD</last_name>
    <phone>33467330924</phone>
    <email>c-chauveton@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent GOEB, PH</last_name>
      <phone>03 22 66 80 00</phone>
      <email>goeb.vincent@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent GOEB, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry SCHAEVERBEKE, PU-PH</last_name>
      <phone>05 56 79 55 45</phone>
      <email>thierry.schaeverbeke@chu-pellegrin.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry SCHAEVERBEKE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain SARAUX, PU-PH</last_name>
      <phone>02 98 34 77 07</phone>
      <email>alain.saraux@univ-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Alain SARAUX, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin SOUBRIER, PU-PH</last_name>
      <phone>04 73 75 14 88</phone>
      <email>msoubrier@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Martin SOUBRIER, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier MARIETTE, PU-PH</last_name>
      <phone>01 45 21 37 58</phone>
      <email>xavier.mariette@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier MARIETTE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle DERNIS, PH</last_name>
      <phone>02 43 43 26 56</phone>
      <email>edernis@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle DERNIS, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BERTIN, PU-PH</last_name>
      <phone>05 55 05 68 70</phone>
      <email>phillipe.bertin@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Phillipe BERTIN, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thao PHAM, PU-PH</last_name>
      <phone>04 91 38 34 62</phone>
      <email>thao.pham@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Thao PHAM, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques MOREL, PU-PH</last_name>
      <phone>04 67 33 87 10</phone>
      <email>j-morel@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jacques MOREL, PU-PHH</last_name>
      <phone>04 67 33 91 71</phone>
      <email>a-remy@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jacques MOREL, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>DAIEN claire, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marlene GENTY, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital L'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liana EULLER-ZIEGLER, PU-PH</last_name>
      <phone>04 92 03 55 12</phone>
      <email>euller-ziegler.l@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Liana EULLER-ZIEGLER, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Carémeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile GAUJOUX-VIALA, PH</last_name>
      <phone>04 66 68 31 20</phone>
      <email>cecile.gaujoux.viala@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile GAUJOUX-VIALA, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Orléans - Hôpital La Source</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie RIST, PH</last_name>
      <phone>02 38 74 40 14</phone>
      <email>stephanie.rist@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie RIST, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis BERENBAUM, PU-PH</last_name>
      <phone>01 49 28 25 20</phone>
      <email>francis.berenbaum@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Francis BERENBAUM, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno FAUTREL, PU-PH</last_name>
      <phone>01 42 17 76 21</phone>
      <email>bruno.fautrel@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno FAUTREL, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleth PERDRIGER, PU-PH</last_name>
      <phone>02 99 26 71 40</phone>
      <email>aleth.perdriger@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Aleth PERDRIGER, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bois Guillaume</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier VITTECOQ, PU-PH</last_name>
      <phone>02 32 88 90 19</phone>
      <email>olivier.vittecoq@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier VITTECOQ, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert MAROTTE, PH</last_name>
      <phone>04 77 12 76 43</phone>
      <email>hubert.marotte@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Hubert MAROTTE, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques-Eric GOTTENBERG, PU-PH</last_name>
      <phone>03 88 12 79 33</phone>
      <email>jacques-eric.gottenberg@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques-Eric GOTTENBERG, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud CONSTANTIN, PU-PH</last_name>
      <phone>05 61 77 69 76</phone>
      <email>constantin.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud CONSTANTIN, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe GOUPILLE, PU-PH</last_name>
      <phone>02 47 47 59 17</phone>
      <email>goupille@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe GOUPILLE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHPG Monaco - Hôpital Prince Grace de Monaco</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BROCQ, PH</last_name>
      <phone>00 377 97 98 84 02</phone>
      <email>obrocq@chpg.mc</email>
    </contact>
    <investigator>
      <last_name>Olivier BROCQ, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antipneumococcal vaccination</keyword>
  <keyword>Methotrexate treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

